Work

Abstract B48: A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.

Year: 2013

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-13-b48

Authors: S. Lindsey Davis, Patricia LoRusso, Lu Xu, Ann M. Kapoun, Jakob Dupont, Pamela Munster, S. Gail Eckhardt, Amita Patnaik

Institutions: University of Colorado Denver, The Barbara Ann Karmanos Cancer Institute, OncoMed (United States), University of California, San Francisco, South Texas Accelerated Research Therapeutics

Language: English

Topic: Cancer Cells and Metastasis

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1985302396

Cites:

Cited by: 7

Related to: 10